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ARTICLE
Effects of route of administration on oxytocin-
induced changes in regional cerebral blood
flow in humans
D.A. Martins1, N. Mazibuko1, F. Zelaya1, S. Vasilakopoulou1, J. Loveridge1, A. Oates2, S. Maltezos3,4,
M. Mehta 1, S. Wastling1,5,6, M. Howard 1, G. McAlonan7, D. Murphy 7, S.C.R. Williams1, A. Fotopoulou8,
U. Schuschnig9 & Y. Paloyelis 1✉
Could nose-to-brain pathways mediate the effects of peptides such as oxytocin (OT) on brain
physiology when delivered intranasally? We address this question by contrasting two
methods of intranasal administration (a standard nasal spray, and a nebulizer expected
to improve OT deposition in nasal areas putatively involved in direct nose-to-brain transport)
to intravenous administration in terms of effects on regional cerebral blood flow during two
hours post-dosing. We demonstrate that OT-induced decreases in amygdala perfusion, a key
hub of the OT central circuitry, are explained entirely by OT increases in systemic circulation
following both intranasal and intravenous OT administration. Yet we also provide robust
evidence confirming the validity of the intranasal route to target specific brain regions. Our
work has important translational implications and demonstrates the need to carefully con-
sider the method of administration in our efforts to engage specific central oxytocinergic
targets for the treatment of neuropsychiatric disorders.
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Over the past decade, robust evidence from preclinicalstudies has demonstrated the importance of the centralOT system in the development1 and regulation of social
behaviour2,3, the modulation of pain processing4, feeding beha-
viour5 and neuroinflammation after brain ischemia6. Harnessing
the central OT system has been identified as a promising strategy
in translational neuroscience for the development of targeted
pharmacological interventions to improve outcome in several
conditions currently lacking efficacious treatments (e.g. autism
spectrum disorder7, schizophrenia8, migrain9, stroke6, obesity10,
Prader-Willi11).
Human studies almost exclusively target the central OT system
by administering synthetic OT using nasal sprays, despite a lack
of understanding of the mechanisms underpinning its pharma-
codynamic effects. OT is a hydrophilic cyclic nonapeptide and is
unable to cross the blood-brain barrier (BBB) in significant
amounts12. The intranasal administration of OT has been
favoured under the assumption that once in the nasal cavity, OT
can reach the brain directly, bypassing the BBB13. Two main
mechanisms have been suggested to underpin the direct nose-to-
brain transport14. The first mechanism postulates internalization
of OT into olfactory or trigeminal neurons innervating the pos-
terior and middle areas of the nasal cavity, followed by axonal
transport and central exocytosis. However, this mechanism would
be slow15 and therefore could not account for the central and
behavioural effects we observe within 15–60 min post-dosing in
humans16. The second mechanism postulates that OT reaches the
cerebrospinal fluid (CSF) and brain parenchyma via passive dif-
fusion through perineural clefts in the nasal epithelium, which
provide a gap in the blood-brain barrier17. While some animal
work is consistent with the existence of the second mechanism18,
there is a lack of robust evidence to support the existence of nose-
to-brain transport in humans15,19.
The lack of clarity regarding the mechanisms mediating the
effects of intranasal OT in humans and the inconsistent results in
existing studies and clinical trials using intranasal sprays to
deliver OT20 have raised questions about the validity of the
intranasal route to administer OT to the brain. While very small
amounts of intranasally administered OT have been reported to
reach the CSF15, peripheral concentrations in the blood are also
increased to supraphysiologic levels. The increase in plasma OT
levels unavoidably engages OT receptors expressed throughout
the body15 and may impact indirectly on brain function and
behaviour. It is also possible that the small amount of synthetic
OT that crosses the BBB from systemic circulation15 may be
sufficient to induce functional effects in the brain, either by
directly activating receptors in the brain or by stimulating OT
autoreceptors on OT-synthesizing hypothalamic neurons to
induce the release endogenous OT15. These mechanisms might
account for the effects of peripherally administered OT (e.g.
intravenous infusion) on behaviour21–24.
Intranasal delivery allows for fast absorption of small molecules
into the peripheral circulation25,26, at the cost of poor and
unreliable control of the amount of the drug absorbed25,26.
Therefore, to achieve significant translational advances, we need
to confirm whether nasal pathways can be used to target the
central OT system and whether they offer any advantage in
relation to alternative methods.
The absence of a selective radiolabelled OT ligand in humans
makes it impossible to directly examine the central penetration
and distribution of synthetic OT after intranasal administration.
An alternative strategy is to quantify whole-brain functional
effects after OT administration. We have previously demon-
strated the sensitivity of arterial spin labelling (ASL) magnetic
resonance imaging (MRI) in quantifying changes in brain’s
physiology after intranasal OT administration16, as reflected in
changes in regional cerebral blood flow (rCBF) at rest, which
provide a quantitative, non-invasive pharmacodynamic marker of
the effects of acute doses of psychoactive drugs27,28, with high-
spatial resolution and excellent temporal reproducibility29. As a
result of neuro-vascular coupling, changes in rCBF are likely
to reflect changes in neuronal activity30, and they capture
relevant differential neurotransmitter activity of neurochemical
systems16,31.
In this study, we use ASL MRI to investigate and compare the
changes in rCBF that follow intranasal and intravenous OT
administration over 104 min post-dosing (Fig. 1). The use of an
intravenous comparator can illuminate whether intranasal OT-
induced changes in brain perfusion in humans result from con-
comitant increases in systemic OT circulation. Standard nasal
sprays were not designed to maximise deposition in the olfactory
and respiratory epithelia that is thought to mediate nose-to-brain
transport32. Therefore, alongside a standard nasal spray, we used
a nasal administration method (PARI SINUS nebuliser) that
combines the production of small size droplets with vibration to
maximize deposition in upper and posterior regions of the nasal
cavity where the nose-to-brain transport putatively occurs33.
We reasoned that if intranasal administration represents a
privileged route for the central delivery of OT, then intranasal
OT-induced changes in rCBF in brain regions typically associated
with the effects of OT in the brain (e.g. the amygdala)34–36 should
not be explained by increases in plasmatic OT achieved after OT
intravenous infusion. Furthermore, if posterior regions of the
nasal cavity are involved in nose-to-brain transport, then using a
device that can increase deposition in these areas may result in a
more robust pattern of changes in rCBF when compared to OT
administration with a standard nasal spray. We demonstrate that
OT-induced decreases in amygdala perfusion, a key hub of the
OT central circuitry, are explained entirely by OT increases in
systemic circulation following both intranasal and intravenous
OT administration. Yet we also provide robust evidence con-
firming the validity of the intranasal route to target specific brain
regions.
Results
Global CBF and subjective state ratings. We observed a linear
decrease over time in participants’ global CBF level and levels of
alertness and excitement (Main effect of time-interval); however,
there was no significant main effect of treatment or time-interval
× treatment interaction (Supplementary Figs. 1 and 2 and Sup-
plementary Table 1). We did not observe any significant corre-
lation between changes in global CBF and ratings of alertness or
excitement over time (Supplementary Fig. 3).
Whole-brain univariate analyses. We first computed a flexible
factorial model to investigate treatment, time-interval and time-
interval × treatment effects on rCBF. We did not observe a sig-
nificant main effect of treatment; however, we found a significant
main effect of time-interval on rCBF in several clusters across the
brain, likely reflecting decreases in alertness and attention. We
observed a significant treatment × time-interval interaction in
three clusters. These clusters spanned: (1) the left superior and
middle frontal gyri and the anterior cingulate gyrus; (2) the right
occipital gyrus, cerebellum, lingual and fusiform gyri, calcarine
cortex, cuneus and inferior temporal gyrus; (3) the left putamen,
caudate nucleus, insula, amygdala, parahippocampal gyrus, rectus
gyrus and medial orbitofrontal cortex (Fig. 2 and Table 1).
We followed up the flexible factorial model with an exhaustive
series of paired t-tests at each time interval to investigate the
direction of potential OT-induced changes in rCBF specifically
for each treatment route (compared to placebo). Results are
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Main effect:
treatment
Main effect:
time-interval
Interaction effect:
treatment × time-interval
2.94
2.01
R L
13.99
2.78
F -statistic
Fig. 2 Whole-brain flexible factorial univariate analysis. We firstly implemented an analysis of covariance design, controlling for global effects on CBF,
using a flexible factorial model in SPM12 where we specified the factors Subjects, Treatment, and Time interval. We present the results of an F test to
investigate the main effects of treatment, i.e. identify brain regions where any treatment induced persistent changes in rCBF (regardless of direction)
across time (first row), and time-interval, i.e. identify brain regions where time induced persistent changes in rCBF (regardless of direction) across
treatments (second row). We also present the results of an F test to investigate the interaction of Treatment × Time-interval i.e. identify brain regions
showing specific treatment-induced changes in rCBF as a function of time interval, regardless of direction (third row). We conducted cluster-level
inference, reporting clusters significant at p < 0.05 FWE-corrected (cluster-forming threshold: p < 0.005, uncorrected). Images are shown as F-statistics in
radiological convention.
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Fig. 1 Study design, drug administration and blood sampling procedures. Upper panel—Drug allocation scheme: In each session, participants received
treatment via all three administration routes, in one of two fixed sequences: either nebulizer/intravenous infusion/standard nasal spray, or standard nasal
spray/intravenous infusion/nebulizer. In 3 out of 4 sessions only one route of administration contained the active drug; in the fourth session, all routes
delivered placebo or saline. Unbeknown to the participants, the first treatment administration method in each session always contained placebo, while
intranasal (spray or nebulizer) OT was only delivered with the third treatment administration. The second administration was an intravenous nfusion of
either saline or oxytocin. Lower panel—Study protocol: After drug administration, participants were guided to the MRI scanner, where eight pulsed
continuous arterial spin labelling (ASL) scans (each lasting ~8min) where acquired, spanning 15–104min after last drug administration offset. We assessed
participants’ levels of alertness and excitement using visual analogue scales (VAS) at three different timepoints during the scanning session to evaluate
subjective drug effects across time. We collected plasma samples at baseline and at five timepoints post-dosing to measure changes in the concentration
of OT and perform pharmacokinetics analysis. (NB Nebulizer, IV Intravenous, pK Pharmacokinetics).
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summarized in Fig. 3 and Tables 2–4. Given the novel and
exploratory nature of these analyses we report the exact FWE-
corrected P-values for significant clusters without further
adjustment for the number of paired t-tests using conservative
Bonferroni correction, and denote in Tables 2–4 with an asterisk
those few clusters with PFWE > 0.002 (P= 0.05/24 tests= 0.002)
following Bonferroni adjustment.
Compared to placebo, synthetic OT when administered with
the standard nasal spray decreased rCBF at 24–32 min post-
dosing in a cluster extending over the left amygdala, left insula,
left parahippocampal gyrus and hippocampus, and left temporal
pole, and at 87–95 min post-dosing in two clusters, one including
the anterior cingulate and the right superior/medial frontal gyri
and another cluster spanning over the brainstem and the right
cerebellum. We further observed significant increases in rCBF at
15–23 min post-dosing, in one cluster spanning the left superior/
middle frontal gyri, supplementary motor area and the precentral
gyrus, at 35–43 min post-dosing over a similar cluster (but
restricted to the left middle/inferior frontal and precentral gyri),
and at 87–95 mins post-dosing in two clusters, one spanning the
superior/middle temporal gyri, the posterior insula and the
postcentral gyrus and another one involving the superior/inferior
parietal lobes, the postcentral and precentral gyri and the
precuneus (all in the left hemisphere) (Table 2).
Intravenous OT decreased rCBF over the same clusters and
time-intervals as for the comparison between standard nasal
sprays vs. placebo, but only in 2 time-intervals. Specifically, we
observed significant decreases in rCBF at 15–23 min post-dosing
in a cluster spanning the amydgala, insula, parahippocampal
gyrus and globus pallidum (all left hemisphere), and at 87–95 min
post-dosing in a cluster extending over the anterior cingulate, the
superior frontal gyrus and the orbitofrontal cortex bilaterally
(Table 3).
The administration of intranasal OT with the nebulizer resulted
in a different pattern of changes compared to standard nasal
spray. Specifically, we observed decreases in rCBF at 15–23min
Table 1 Whole-brain univariate flexible factorial analysis.
Cluster description Hemisphere K Pfwe Peak coordinates Description
x y z
Main effect: method
No cluster survived correction
Main effect: time interval
Cluster 1 Bilateral 295660 <0.001 38 −84 −8 Right inferior
occipital gyrus30 −90 −2
28 −82 14 Right superior
occipital gyrus
Cluster 2 Left 2127 <0.001 −14 −18 −4 Left ventral
diencephalon
−30 −2 −6 Left putamen
−18 −6 26 Left caudate
Cluster 3 Left 2271 <0.001 −48 −52 40 Left angular gyrus
−56 −34 18 Left planum
temporale−42 −32 12
Cluster 4 Left 854 <0.001 −46 −70 −42 Left cerebellum
−18 −70 −36
−30 −64 −38
Cluster 5 Bilateral 2389 <0.001 −12 28 50 Left superior
frontal gyrus
−40 16 52 Left middle
frontal gyrus
−42 24 50
Cluster 6 Right 435 0.022 48 4 42 Right
precentral gyrus50 −2 42
Cluster 7 Right 508 0.010 36 52 −14 Right lateral
orbital gyrus44 44 −14
46 44 −4 Right inferior
frontal gyrus
(triangular part)
Interaction: method × time interval
Cluster 1: superior and middle frontal gyrus, anterior cingulate Left 341 0.040 −18 46 18 Left superior
frontal gyrus−26 56 8
−14 56 4
Cluster 2: inferior, superior and middle occipital gyrus,
cerebellum, lingual gyrus, fusiform gyrus, calcarine cortex,
cuneus, inferior temporal gyrus
Right 905 <0.001 38 −78 −12 Right inferior
occipital gyrus
42 −74 −26 Right cerebellum
16 −86 −2 Right calcarine cortex
Cluster 3: putamen, insula, amygdala, parahippocampal gyrus,
caudate, olfactory region, rectus gyrus and medial
orbitofrontal cortex
Left 407 0.016 −24 12 −14 Left putamen
−20 26 2 Left caudate
−20 24 −8
Clusters showing a significant main effect of treatment, time or treatment × time-interval interaction in rCBF in the 15–104min post-administration period, as identified in F contrasts (not capturing the
direction of the change in rCBF). Global CBF was used as a nuisance variable. We conducted cluster-level inference, reporting clusters significant at p < 0.05 FWE-corrected (cluster-forming threshold:
p < 0.005, uncorrected).
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post-dosing in a cluster spanning the left caudate, left putamen
and pallidum, and at 75–83min post-dosing in a cluster extending
over the left caudate, putamen, pallidum, thalamus, amygdala,
hippocampus, olfactory region and the insula. We also observed
increases in rCBF at 24–32min post-dosing in two clusters,
one spanning the right superior/middle/inferior occipital gyri, the
calcarine sulcus and the cuneus bilaterally, and the other one
the right cerebellum, and at 75–83min post-dosing in a cluster
spanning the postcentral gyrus, the superior/middle/inferior
occipital gyri, the superior parietal gyrus, the inferior/middle
temporal gyri, the precuneus, the calcarine sulcus and the cuneus,
all in the right hemisphere. Accounting for plasma OT AUC had
no effect on the changes in rCBF observed following administra-
tion with the nebulizer (Table 4).
Table 2 Paired t-contrasts comparing standard spray OT to placebo/saline.
Cluster description Hemisphere K Pfwe Peak coordinates Description
x y z
Spray > placebo (15–23min)
Cluster 1: superior/middle frontal gyrus,
supplementary motor area, precentral gyrus
Left 1500 <0.001 −24 24 64 Left superior/middle frontal gyrus
−26 28 46
−24 16 68
Spray < placebo (24–32min)
Cluster 2: parahipocampal gyrus, temporal pole,
amygdala, insula, hippocampus
Left 1295 <0.001 −34 8 −20 Left temporal pole
−16 −6 −34 Left enthorinal area
−18 −6 −26 Left enthorinal area
Spray > placebo (35–43min)
Cluster 3: middle and inferior frontal gyrus,
precentral gyrus
Left 999 <0.001 −42 40 34 Left middle frontal gyrus
−54 20 38
−42 46 28
Spray > placebo (87–95min)
Cluster 4: superior and middle temporal gyrus, insula,
postcentral gyrus
Left 1848 <0.001 −56 −46 2 Left middle/superior temporal gyrus
−66 −20 30 Left postcentral/supramarginal gyrus
−60 −46 −8 Left middle temporal gyrus
Cluster 5: superior and inferior parietal lobe,
postcentral and precentral gyrus, precuneus
Left 1315 <0.001 −18 −54 52 Left superior parietal lobe
−36 −44 52 Left superior parietal lobe/
supramarginal gyrus
−24 −20 66 Left precentral gyrus
Spray < placebo (87–95min)
Cluster 6: anterior cingulate, right superior and medial
frontal gyrus
Right 1350 <0.001 24 46 12 Right middle frontal gyrus
Right 16 46 12 Right superior frontal gyrus
Bilateral −2 36 28 Anterior cingulate gyrus
Cluster 7: brainstem and cerebellum* Bilateral 591 0.01 6 −40 −56 Brainstem
Right 14 −48 −56 Right cerebellum
Bilateral 6 −38 −32 Brainstem
We compared CBF maps following standard spray OT and placebo administration using paired t-contrasts at each time-interval (to capture the direction of potential rCBF changes), controlling for global
CBF as a nuisance variable. We conducted cluster-level inference, reporting clusters significant at p < 0.05 FWE-corrected (cluster-forming threshold: p < 0.005, uncorrected). Clusters that do not
survive correction for multiple testing following adjustment of the P-value using Bonferroni correction for the 24 paired-t-tests performed are denoted by an asterisk (*) (Padjusted= 0.05/24= 0.002).
Spray
Intravenous
Nebulizer
a
b
c
Time from last drug
administration offset (mins) 15–23 24–32
R L
35–43 75–83 87–95 96–104
2.97
2.97
8.85
6.97
T -statistic
Fig. 3 Whole-brain characterisation of the changes in rCBF associated with each method of administration. For each time-point, we compared CBF maps
between treatment and placebo using Paired T-contrasts, accounting for global CBF as a nuisance variable. We conducted cluster-level inference, reporting
clusters significant at p < 0.05 FWE-corrected (cluster-forming threshold: p < 0.005, uncorrected). Images are shown as t-statistics in radiological
convention. Blue and red indicate decreases and increases in rCBF, respectively. The first row (Panel a) refers to rCBF changes associated with the nasal
spray, the second (Panel b) with the intravenous administration and the third one (Panel c) with the PARI SINUS nebulizer.
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Decreases in rCBF observed after standard nasal spray and
intravenous OT administration at 24–32 and 87–95 min post-
dosing overlap anatomically to a substantial extent (Fig. 4). We
thus followed up with a direct comparison of standard nasal spray
vs. intravenous OT administration using paired sample t-tests
for these time-intervals; we did not observe any significant
differences in rCBF between the two administration methods.
Individual differences in OT concentration (AUC over 120 min
post-dosing) in plasma post-dosing were negatively correlated
with OT-induced changes in rCBF in the two spatially over-
lapping clusters showing significant decreases in rCBF in the
comparisons of nasal spray OT vs. placebo and intravenous OT
vs. saline (Fig. 5), but not with any other OT-induced changes,
irrespective of method of administration, time-interval or
direction of effect (Supplementary Table 3). Accounting for
plasma OT AUC in the paired t-test for the standard nasal spray
vs. placebo and the intravenous OT vs. saline comparisons
eliminated all significant decreases in rCBF that were observed for
each of these administration methods. However, accounting for
plasma OT AUC had no effect on the changes in rCBF uniquely
observed in the standard nasal spray vs. placebo comparison.
Comparison of pharmacokinetic profiles among treatments.
OT reached peak plasma concentration at the end of dosing when
administered intravenously or via nasal spray, and by ~15 min
post-dosing when administered with the nebulizer (Fig. 6a).
Intravenous peak plasma OT concentrations (Cmax) were sig-
nificantly higher than either intranasal administration method,
while Cmax did not differ between the nasal administration
Table 4 Paired t-contrasts comparing OT administered with the nebulizer to placebo/saline.
Cluster description Hemisphere K Pfwe Peak coordinates Description
x y z
Nebulizer < placebo (15–23min)
Cluster 1: caudate, putamen, pallidum* Left 434 0.037 −18 0 20 Left caudate
−12 8 8
−6 2 16
Nebulizer > placebo (24–32min)
Cluster 2: superior, middle and inferior occipital gyrus, calcarine
sulcus, cuneus
Bilateral 1154 <0.001 52 −74 −8 Right inferior
occipital gyrus38 −92 −2
40 −88 −14
Cluster 3: cerebellum* Right 457 0.033 26 −72 −28 Right cerebellum
12 −82 −28
4 −86 −38
Nebulizer > placebo (75–83min)
Cluster 4: postcentral gyrus, superior, middle and inferior occipital
gyrus, superior parietal gyrus, inferior and middle temporal gyrus,
precuneus, calcarine sulcus, cuneus
Right 2546 <0.001 56 −66 −16 Right inferior
temporal gyrus
28 −54 72 Right Superior
Parietal Lobule
48 −78 −16 Right inferior
occipital gyrus
Nebulizer < placebo (75–83min)
Cluster 5: caudate, putamen, pallidum, thalamus, amygdala,
hippocampus, olfactory region, insula
Left 1229 <0.001 −14 0 18 Left caudate
−12 −14 −10 Left ventral diencephalon
−6 −6 4 Left thalamus
We compared CBF maps following OT administered with the nebulizer to placebo/saline using paired t-contrasts at each time-interval (to capture the direction of potential rCBF changes), controlling for
global CBF as a nuisance variable. We conducted cluster-level inference, reporting clusters significant at p < 0.05 FWE-corrected (cluster-forming threshold: p < 0.005, uncorrected). Clusters that do not
survive correction for multiple testing following adjustment of the P-value using Bonferroni correction for the 24 paired-t-tests performed are denoted by an asterisk (*) (Padjusted= 0.05/24= 0.002).
Table 3 Paired t-contrasts comparing intravenous OT administration to placebo/saline.
Cluster description Hemisphere K PFWE Peak Coordinates Description
x y z
Intravenous < placebo (24–32min)
Cluster 1: parahippocampal gyrus, pallidum, amygdala, insula Left 1159 <0.001 −12 4 −2 Left pallidum
−16 2 −20 Left enthorinal area/
amygdala
−38 2 −10 Left anterior insula
Intravenous < placebo (87–95min)
Cluster 2: anterior cingulate, superior frontal gyrus,
orbitofrontal cortex
Bilateral 1179 <0.001 6 42 16 Right anterior cingulate
14 62 12 Right superior frontal gyrus
10 56 −6 Right superior frontal gyrus
We compared CBF maps following intravenously administered OT and placebo/saline using paired t-contrasts at each time-interval (to capture the direction of potential rCBF changes), controlling for
global CBF as a nuisance variable. We conducted cluster-level inference, reporting clusters significant at p < 0.05 FWE-corrected (cluster-forming threshold: p < 0.005, uncorrected). Clusters that do not
survive correction for multiple testing following adjustment of the P-value using Bonferroni correction for the 24 paired-t-tests performed are denoted by an asterisk (*) (Padjusted= 0.05/24= 0.002).
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methods (Supplementary Table 2) (Repeated measures One-way
ANOVA: F(1.38,22.02)= 92.39, p < 0.0001, η2p= 0.815, post-hoc
tests: Spray vs Nebulizer—p= 0.972; Spray vs Intravenous—p <
0.0001; Nebulizer vs Intravenous—p < 0.0001). As intended, the
intravenous OT infusion resulted in significantly higher AUC
over the observation interval, while the intranasal methods did
not differ in terms of AUC (Fig. 6b) (Supplementary Table 2)
(Repeated measures One-way ANOVA: F(1.15,24.24)= 20.47, p <
0.001, η2p= 0.7460; post-hoc tests: Spray vs Nebulizer—p=
0.1061; Spray vs Intravenous—p= 0.0053; Nebulizer vs Intrave-
nous—p < 0.0001). There were no significant differences in the
absolute bioavailability of OT absorbed to the plasma between the
standard nasal spray and PARI SINUS nebulizer (Fig. 6c) (Sup-
plementary Table 2) (Paired t-test: T(15)= 1.662, p= 0.129, d=
0.416).
Regional temporal dynamics of pharmacological effects. We
present in Fig. 7 graphs depicting changes over time in regional
perfusion in anatomical regions of interest (ROIs) corresponding
to clusters showing significant OT-induced rCBF changes (com-
pared to placebo) for each method of administration in the
whole-brain univariate analyses. Overall, these graphs show that
the temporal dynamics of the effects of synthetic oxytocin
administration on brain perfusion is complex and shows regional
specificities. Depending on the region of the brain, the effects can
start or be maximal at different times post-dosing and extend
over different periods of time. For instance, Fig. 7 shows that the
OT-induced decrease in left amygdala perfusion is largely an early
effect, maximal in the first few minutes (<25 min) after OT
administration and independent of method of administration. In
contrast, the OT-induced rCBF increase observed in the posterior
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Fig. 5 Changes in rCBF associated with systemic OT are predicted plasma OT post-dosing. To investigate if concomitant increases in peripheral OT were
related to treatment-induced changes in rCBF, we extracted data from each significant rCBF cluster in the paired sample t-tests and calculated Spearman
correlation coefficients between these contrasts estimates and the areas under the curve (AUCs) reflecting individual differences in treatment-induced OT
plasma concentrations for the corresponding method of administration. In panel a, we present decreases in rCBF after spray OT at 24–32min post-dosing;
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Fig. 4 Intravenous and Spray OT decreased rCBF in areas overlapping
anatomically. Panel a refers to rCBF changes identified at 24–32min post-
dosing; Panel b refers to rCBF changes identified at 87–95min post-dosing.
In yellow we present the voxels where OT intravenous administration
decreased rCBF at these timepoints, while blue refers to the voxels where
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conducted cluster-level inference, reporting clusters significant at p < 0.05
FWE-corrected (cluster-forming threshold: p < 0.005, uncorrected). Images
are shown as binary clusters in radiological convention.
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insula after administration by standard nasal spray tends to be
more sustained in time and maximal at later time-intervals.
Heart rate and heart-rate variability. There were no significant
main effects of treatment or time-interval, and no significant
treatment × time-interval effects on heart rate or on any time
domain, frequency domain or nonlinear measures of heart-rate
variability (Supplementary Table 5).
Discussion
This is the first in man study to investigate the pharmacody-
namics of synthetic oxytocin on resting rCBF over an extended
period of time when administered intravenously, with a nebulizer
or a standard nasal spray. Our study yielded three key findings,
which we discuss below in turn.
Our first key finding was the observation of OT-induced
decreases in rCBF in the left amygdala and the anterior cingulate
cortex with both the intravenous and standard nasal spray
administration methods at overlapping temporal intervals. These
decreases in rCBF in both the left amygdala and anterior cingulate
cortex correlated with nasal spray or intravenous-induced increases
in OT plasma concentrations, and became non-significant when
these concomitant changes in OT plasma concentration were
added as a covariate in the model. At the same time, concomitant
change in plasma OT concentration did not correlate with or
account for any of the remaining changes in rCBF, when OT was
administered intranasally either with a standard nasal spray or the
nebulizer.
The suppression of amygdala’s activity constitutes one of the
most robust findings in animal studies and intranasal OT studies
in men34,37–39. Similarly, human BOLD fMRI studies have
implicated intranasal OT-induced decreases in BOLD in the
anterior cingulate cortex in the modulation of social cognition40,
emotion41 or fear consolidation42 effects. These suppressive
effects on BOLD match our observation of decreases in rCBF in
these areas at rest—which we suggest is likely to reflect decreases
in local metabolic demands associated with decreasing neural
activity at rest. We provide first evidence that the intravenous
infusion of OT echoes the effects of a standard spray adminis-
tration on brain’s physiology within key neural circuits at rest.
These effects are consistent with previous observations of
improved repetitive behaviours and social cognition in ASD
patients after intravenous administration of OT21–24 and provide
a possible mechanism by which these therapeutical effects may
arise. Therefore, our findings challenge the current assumption
that key effects of intranasal OT on brain function and behaviour
are entirely derived by direct nose-to-brain transport.
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Fig. 6 Spray and nebulized OT result in similar pharmacokinetics profiles in the plasma. From the plasmatic concentrations of OT at several timepoints
after dosing, we calculated the area under the curve (AUC) using the trapezoidal rule for each subject and session. We also determined the absolute
bioavailability of OT in systemic circulation for each of the intranasal methods of administration, calculated as the dose-corrected AUC of each intranasal
administration divided by the dose-corrected AUC of the intravenous administration. Mean AUCs were compared between the three methods of
administration with a repeated measures one-way analysis of variance, using the Greenhouse-Geisser correction against violations of sphericity. Post-hoc
comparisons between methods were implemented using Tukey’s correction for multiple comparisons. Mean absolute bioavailabilities were compared
between the standard nasal spray and the PARI SINUS nebulizer using a two-tailed paired t-test. In panel a, we present the variations of the concentrations
of OT in plasma across time; in panel b, we present the results of the comparison of AUCs between treatments; and in panel c, we present the comparison
of absolute plasmatic bioavailability between spray and nebulizer. Data are presented as mean ± 1 standard error of the mean (SEM). Error bars correspond
to SEM. Statistical significance was set to p < 0.05 (two-tailed). Source data are provided as a Source Data file.
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With respect to changes in rCBF induced by the intravenous
administration of OT, there may be three possible mediating
mechanisms. First, it is possible that peripheral effects of OT on
vegetative territories, such as the heart, may be an indirect source
of changes in areas of the interoceptive/allostasis network in the
human brain, where the dorsal amygdala and the pregenual
anterior cingulate cortex assume the role of visceromotor hubs43.
However, as we did not observe any effects of OT (irrespective of
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administration method) on heart rate or heart-rate variability,
this cannot explain the decreases in rCBF we observed in this
study. Second, it is possible that the small amounts of OT that
cross the BBB15 (or a functional metabolite) is sufficient to induce
changes in rCBF in brain regions of high density of the OT
receptor, such as the amygdala, but not in other regions where the
lower availability of the receptor would require higher local
concentrations44. This hypothesis is in line with three recent
studies. The first study reported that the intravenous infusion of
labelled synthetic OT increased synthetic OT levels in the CSF in
primates45. The second study found that synthetic OT when
administered intraperitoneally increased the concentration of OT
in the extracellular fluid in the amygdala and dorsal hippo-
campus, both in wild-type and OT knockout mice46. The third
study showed that circulating OT can be transported into the
brain47. Third, it is possible that the small amount of synthetic
OT crossing the BBB is sufficient to engage OT-synthesising
neurons in the hypothalamus, inducing the release of endogenous
OT in the brain48. However, a recent study in primates that
administered labelled OT did not support this hypothesis45.
Our second key finding was the observation of increases in
rCBF following intranasal administration (using either a standard
nasal spray or the nebulizer), which could not be explained by
concomitant increases in plasma OT. Indeed, there were no sig-
nificant increases in rCBF (even at a lower threshold) when OT
was administered intravenously. This finding is consistent with
the contribution of nose-to-brain pathways for these effects of
intranasal OT in humans. It matches well recent evidence
showing that the intranasal administration of OT in mice
increased the concentrations of OT in the extracellular fluid of the
amygdala beyond those achieved with the intraperitoneal
administration of a dose matched to result in similar plasmatic
elevations46.
Our third key finding was that while the application of the
same nominal dose of intranasal OT (40IU) with the standard
nasal spray and the nebulizer resulted in identical pharmacoki-
netic profiles, the patterns of OT-induced changes in rCBF were
markedly different across the two methods of intranasal admin-
istration. Given the similarity in pharmacokinetic profiles, we
hypothesize that the difference in the patterns of OT-induced
rCBF changes achieved with each method can only be explained
by differences in the deposition of OT in the olfactory and
respiratory regions and the parasinusal cavities, which receive
innervation from the olfactory and trigeminal nerves and may
thus constitute points of entry to the brain. It is possible that, as
expected, the nebulizer achieved higher OT deposition in these
areas32 and hence resulted in increased amounts of OT reaching
the brain (compared to the standard nasal spray). Consistent with
this hypothesis, we found that OT induced increases in rCBF in
brain regions more posterior and distant from the point of entry,
such as the visual cortices. These areas, although expressing
relatively low levels of the OTR, are enriched in the expression
of the vasopressin receptor 1 (V1aR) mRNA (Supplementary
Fig. 4); OT has considerable affinity for the V1aR in higher
concentrations49. The higher central concentrations of OT
achieved with the nebulizer may have allowed the peptide to
diffuse farther and hence activate the V1aR that would not have
been targeted by lower local concentrations of the peptide. This
hypothesis assumes that the amounts delivered with the nasal
spray do not saturate the nose-to-brain pathway, if it exists.
The fact that the nebulizer resulted in a different pattern of
rCBF changes, with null or minimal overlap with the changes
observed after the standard spray, instead of simply observing
changes in the magnitude of the effects within the same areas, is
surprising to some extent. We hypothesized that the nebulizer
would result in changes similar to those achieved by the spray but
of higher magnitude. We also considered that the nebulizer might
modulate rCBF in areas that were not targeted either by the spray
or the intravenous administrations. However, this prediction
would only have been valid if the pharmacodynamics of the rCBF
response to OT followed a linear model—which does not seem to
be the case at least for some brain areas. The few studies that have
inspected the dose-response effects of intranasal OT on the BOLD
response in the amygdala support an inverted-U shape curve of
response by showing that deviating from an “optimal” dose may
in fact result in lower or null effects35,50.
We believe the complexity of the central OT signalling
machinery51 should be considered to interpret these findings. The
OTR has been described to recruit different intracellular G pro-
tein (Gs or Gi) pathways, depending on ligand, receptor and G
protein type distribution and abundance44,51. Gs and Gi activa-
tion typically result in opposite effects in terms of cellular func-
tion52, meaning that in areas of high density of Gi proteins higher
amounts of OT may in fact result in inhibition of neuronal
activity or null effects44,51. This complexity might explain, for
instance, why we did not observe changes in rCBF with the
nebulizer in regions where the standard nasal spray produced
effects. Additionally, the lack of OT-induced rCBF changes, when
OT was administered with the nebulizer, in some of the clusters
where we noted significant effects for the nasal spray (such as the
left amygdala and the ACG), might simply be a result of statistical
thresholding. For example, plots of OT-induced changes in rCBF
in the left amygdala, over time, (see Fig. 6) revealed similar OT-
induced decreases in rCBF across all three administration
methods at the first two time intervals. The lack of a significant
OT-induced decrease following administration with the nebulizer
in the whole-brain univariate analysis is likely to reflect the higher
variability of decreases in rCBF, across participants, compared to
the other methods, at these time intervals. Until a ligand allowing
for direct quantification of in vivo penetration of OT in the brain
after intranasal administration might be produced, a dose-
response study using the nebulizer may allow us to gain further
indirect insights about whether using the nebulizer may confer
certain advantages regarding targeting the central OT system.
While our findings are consistent with the idea that nose-to-
brain pathways could contribute to some of the changes in rCBF
induced by intranasal OT, our study cannot illuminate the precise
mechanisms underlying these effects. We believe that most
Fig. 7 Regional temporal dynamics of rCBF changes in key anatomical regions of interest. In order to illustrate the time-course of the changes in rCBF for
each method of administration in key brain areas showing significant OT-induced changes in rCBF in the whole-brain univariate analyses, we estimated and
plotted mean rCBF values over-time from anatomical regions-of-interest (ROIs) corresponding to the identified significant clusters. Each subplot depicts
mean rCBF values (y-axis) at each time-interval (x axis), for each method of administration in each ROI. Regression lines were fitted using a non-parametric
regression method that fits multiple regressions in local neighbourhood (Locally estimated scatterplot smoothing - LOESS) to the time-course of mean
rCBF in each ROI for each method of administration separately (the shadows denote the 95% confidence interval for each fitted line)97. To avoid the
potential confounding effects of nominal changes in global CBF across time or between methods of administration, we used demeaned values of mean ROI
rCBF estimates, which correspond to subtracting global CBF estimates from the raw mean rCBF in each ROI. Source data are provided as a Source Data file.
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evidence to date concurs on the idea that OT, when administered
intranasally, may diffuse from the olfactory and respiratory epi-
thelia in the middle and upper posterior regions of the nasal
cavity along ensheathed channels surrounding the olfactory and
trigeminal nerve fibre pathways and lymphatic vessels to the CSF
and/or the brain53. Research in rodents and monkeys has shown
that molecules administered intranasally can be transported to
the olfactory bulb within a time-frame of 45–90 min54,55, and
possibly much faster56–58. A recent comparison of intranasal and
intravenous administration of a new OT receptor tracer in mice
supported this hypothesis by showing uptake of the intranasally
administered tracer to the olfactory bulb, while increases in this
area after the intravenous administration of the tracer were
almost negligible59. The increases of the concentration of the
tracer in the olfactory bulb following its intranasal administration
could be observed as soon as 30 min post-dosing, which fits the
time-frame of the effects we report in our study. While our
findings cannot illuminate the precise pathway through which
intranasal OT may reach the brain, the fact that we observe
distinct patterns of changes in rCBF with two different intranasal
methods suggests that the changes we see in the brain are unlikely
to be explained by local effects of intranasal OT in the nasal
cavity. Expression of the OT receptor has been reported in human
taste buds60 and in the rat olfactory epithelium61. Direct actions
of OT on olfactory and trigeminal nerve bundles could parsi-
moniously explain the discrepancies between the changes
observed after intranasal and intravenous administration of OT.
If direct modulation of activity in these nerve bundles would
account for all the changes we report for our intranasal admin-
istration methods, then one would expect that the changes
observed in rCBF after intranasal administration of synthetic OT
would be mostly restricted to the olfactory/trigeminal pathways
and respective connected areas, which is not entirely supported
by our data. In fact, the effects we observed after synthetic OT
map to areas where expression of receptors for OT (either the
OTR or the AVPR1A) seem to be present, as per our current
understanding of the distribution of these receptors in the human
brain62,63. While we cannot exclude that some of the effects we
observed after intranasal OT may relate to direct modulation of
activity in nerves bundles, this mechanism is unlikely to fully
account for all the effects we report herein.
Finally, we note that assuming a unique pharmacodynamics
model for the effects of synthetic OT on rCBF, with a single time-
course, may be simplistic. In fact, our data suggest that depending
on the region of the brain, changes in rCBF, compared to placebo,
can start or be maximal at different times post-dosing and extend
over different periods of time. This regional diversity in phar-
macodynamics is not surprising given the known complexity of
the OT signalling machinery, regional variations in receptors
density and in the distribution of OT in the brain as a function of
entry point44,51. Our study may help to guide future studies
aiming to target specific regions by providing an indication of the
time-intervals post-dosing at which these effects may be maximal.
From a translational perspective, our findings emphasize the
inadequacy of a one-fits-all approach in the administration of
synthetic OT to target the central OT system in humans for the
treatment of brain’s disorders. Our findings indicate that some
specificity may be achieved depending on the route used to
deliver OT. Given that enhacement of brain’s metabolism in areas
such as the frontal gyrus, insula or occipital cortices may be
restricted to the intranasal route, clinical applications aiming to
target these circuits should thus prefer this route. However, we
should not completely discard the potential utility of the per-
ipheral route. Systems of controlled sustained drug release for the
peripheral circulation (i.e. transdermal controlled release64)
already in place may provide an excellent opportunity to explore
the clinical value of this route during chronic administrations in
patients.
Our study faces certain limitations. First, the amount of OT
administered intravenously was not chosen to mimic exactly the
plasmatic concentrations achieved after intranasal administra-
tion50. Instead, we adopted a proof-of-concept approach, aiming
to achieve consistently higher plasmatic concentrations of OT
during the full period of scanning. Future studies should include
an intravenous comparator that achieves pharmacokinetic profiles
that are similar to those achieved with the intranasal methods.
Second, our findings cannot be readily extrapolated to women,
given the known sexual dimorphism of the OT system65–67. Third,
although we tested for the potential effects of synthetic OT on
cardiac physiology as a confounder, we acknowledge that potential
effects on other peripheral systems need consideration. Future
studies need to compare the intranasal and intravenous admin-
istration of OT with the parallel administration of a specific non-
brain penetrant OT receptor antagonist to isolate the potential
contribution of OT’s signalling in the periphery. Fourth, we relied
on a biomarker of brain physiology (rCBF) to probe the effects of
different methods of administration of OT on brain function. This
method is an indirect but sensitive signature of regional neuronal
activity68,69; however, it is theoretically susceptible to potential
confounding vascular effects70. While we cannot exclude the
presence of such effects, we do not believe they are an important
confounder of our results for two reasons: first, if the effects we
observed after synthetic OT solely reflected drug effects on vas-
culature, then we should expect to see the same effects when
administering OT intranasally and intravenously as both routes
increase the concentration of the peptide in the systemic circula-
tion to supraphysiologic levels—this is not what we found; second,
vascular effects are likely to be reflected on changes in global brain
perfusion, but our results did not show any significant effects of
any treatment on global CBF—in fact, we included global CBF as a
nuisance variable in all of our analyses, therefore accounting for
unspecific global vascular effects on CBF. The idea that the
reported effects of OT on rCBF do not reflect unspecific vascular
effects on global perfusion is further supported by preclinical data
showing that the modulation of rCBV by intranasal OT in rodents
is likely to result from neural activity71. Finally, the univariate
analyses we present in this paper should not be used to define the
temporal dynamics of the effects of synthetic OT on rCBF (as has
been previously explored using pattern recognition analyses)16
because of the risk of false negatives in specific time-intervals.
Instead, we provide the time-courses of perfusion in the areas
where we found significant OT-induced changes in rCBF in the
whole-brain univariate analyses (Fig. 7), which the reader may use
to gain insight about the diversity of the pharmacological effects
on a regional basis.
In conclusion, we provide evidence consistent with the invol-
vement of nose-to-brain pathways to the changes in brain phy-
siology observed after intranasal synthetic OT in humans. At the
same time, we also demonstrate that some of the key effects of
synthetic OT in the human brain, when delivered by standard
nasal sprays, can be explained by concomitant increases in per-
ipheral OT levels post-dosing. Our results emphasize the inade-
quacy of a one-fits-all approach in the administration of synthetic
OT to modulate brain function for the treatment of psychiatric
or neurological conditions in humans, while highlighting the
importance of optimizing the delivery of peptides to the brain
through nose-to-brain pathways.
Methods
Participants. We recruited 17 healthy male adult volunteers (mean age 24.5, SD=
5, range 19–34 years). One participant did not complete one of the four visits and
for this reason was excluded from all analyses. We screened participants for
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psychiatric conditions using the Symptom Checklist-90-Revised72 and the Beck
Depression Inventory-II73 questionnaires. Participants were not taking any pre-
scribed drugs, did not have a history of drug abuse and tested negative on a urine
panel screening test for recreational drugs, consumed <28 units of alcohol per week
and <5 cigarettes per day. We instructed participants to abstain from alcohol and
heavy exercise for 24 h and from any beverage or food for 2 h before scanning.
Participants gave written informed consent. King’s College London Research Ethics
Committee (PNM/13/14-163) approved the study. We determined sample size
based on our previous validation study demonstrating that N= 16 per group was
sufficient to quantify standard nasal spray OT-induced changes in rCBF in a
between-subjects design16,74.
Study design. We employed a double-blind, placebo-controlled, triple-dummy,
crossover design. Participants visited our centre for four experimental sessions
spaced 8.90 days apart on average (SD= 5.65, range: 5–28 days). In each session,
participants received treatment via all three administration routes, in one of two
fixed sequences: either nebulizer/intravenous infusion/standard nasal spray, or
standard nasal spray/intravenous infusion/nebulizer, according to the treatment
administration scheme presented in Fig. 1. In three out of four sessions only one
route of administration contained the active drug; in the fourth session, all routes
delivered placebo or saline. Participants were randomly allocated to a treatment
order (i.e. a specific plan regarding which route delivered the active drug in each
experimental session) that was determined using a Latin square design. Unbe-
known to the participants, the first treatment administration method in each
session always contained placebo (see Administration 1 in Fig. 1), while intranasal
(spray or nebulizer) OT was only delivered with the third treatment administra-
tion. This protocol maintained double-blinding while avoiding the potential
washing-out of intranasally deposited OT (as might be the case if OT had been
administered at the first treatment administration point and placebo at the third
administration point).
Intranasal OT administration. For the intranasal administrations, participants
self-administered a nominal dose of 40 IU OT (Syntocinon; 40IU/ml; Novartis,
Basel, Switzerland), one of the highest clinically applicable doses75. We have shown
that 40IU delivered with a standard nasal spray induce robust rCBF changes in the
human brain in a between-subjects, single-blind design study16. For the intranasal
administration, we used specially manufactured placebo that contained the same
excipients as Syntocinon except for oxytocin.
Standard nasal spray administration: Participants self-administered 10 puffs,
each containing 0.1 ml Syntocinon (4IU) or placebo, one puff every 30 s,
alternating between nostrils (hence 40IU OT in total). The aerosol droplet size of
three Syntocinon spray bottles was assessed by laser diffraction (Malvern Spraytec,
Malvern Panalytical, Worcestershire, UK). The mass median diameter (MMD) of
the aerosol plume was 37 ± 2.5 µm.
PARI SINUS nebulizer: Participants self-administered 40IU OT (Syntocinon) or
placebo, by operating the SINUS nebulizer for 3 min in each nostril (6 min in total),
according to instructions. The correct application of the device was confirmed by
determining gravimetrically the administered volume. Participants were instructed
to breathe using only their mouth and to keep a constant breath rate with their soft
palate closed, to minimize delivery to the lungs. The PARI SINUS (PARI GmbH,
Starnberg, Germany) is designed to deliver aerosolised drugs to the sinus cavities
by ventilating the sinuses via pressure fluctuations. The SINUS nebulizer produces
an aerosol with 3 µm MMD, which is superimposed with a 44 Hz pulsation
frequency. Hence, droplet diameter is roughly one tenth of a nasal spray and its
mass is only a thousandth. The efficacy of this system was first shown in a
scintigraphy study by ref. 76. Since the entrance of the sinuses is located near the
olfactory region, an improved delivery to the olfactory region was expected
compared to nasal sprays. Other studies32 have shown up to 9.0% (±1.9%) of the
total administered dose to be delivered to the olfactory region, 15.7 (±2.4%) to the
upper nose.
Intravenous OT administration. For the intravenous administration, we delivered
10IU OT (Syntocinon injection formulation, 10IU/ml, Alliance, UK) or saline via
slow infusion over 10 min (1IU/min). A 50-ml syringe was loaded with either 32 ml
of 0.9% sodium chloride (placebo) or 30 ml of 0.9% sodium chloride with 2 ml of
Syntocinon (10IU/ml). A Graseby pump was used to administer 16 ml of the
compound (hence 10IU of OT in total) over 10 min, at a rate of 96 ml/h. The ECG
was monitored during the intravenous administration interval. We selected the
intravenous dose and rate of administration to assure high plasmatic concentra-
tions of OT throughout the observation period while restricting cardiovascular
effects to tolerable and safe limits. A rate of 1IU per minute is typically used in
caesarean sections and is considered to have minimised side effects77,78.
Procedure. Each experimental session began with the treatment administration
protocol that lasted about 22 min in total (Fig. 1). After drug administration,
participants were guided to the MRI scanner, where eight pulsed continuous
arterial spin labelling scans (each lasting approx. eight minutes) where acquired,
spanning 15–104 min post-dosing, as detailed in Fig. 1. Participants were instructed
to lie still and maintain their gaze on a centrally placed fixation cross during
scanning. We assessed participants’ levels of alertness (anchors: alert-drowsy) and
excitement (anchors: excited-calm) using visual analogue scales (0–100) at three
different timepoints during the scanning session (the first one immediately before
the first scan—around 15 mins post-dosing, the second one immediately after the
fourth scan—around 55 mins post-dosing and the last one immediately before the
seventh scan—around 92 mins post-dosing) to evaluate subjective drug effects
across time. An 8-min resting state BOLD fMRI scan was obtained at about 60 min
post-dosing (data not presented here).
Blood sampling and plasmatic OT quantification. We collected plasma samples
at baseline and at five timepoints post-dosing (as detailed in Fig. 1) to measure
changes in the concentration of OT. Plasmatic OT was assayed by radio-
immunoassay (RIAgnosis, Munich, Germany) after extraction, currently the gold-
standard technique for OT quantifications in peripheral fluids79. The detection
limit of this assay is in the 0.5 pg/sample range. Cross-reactivity with vasopressin,
ring moieties and terminal tripeptides of both OT and vasopressin and a wide
variety of peptides comprising 3 (alpha-melanocyte-stimulating hormone) up to 41
(corticotrophin-releasing factor) amino acids are <0.7% throughout. The intra- and
inter-assay variabilities are <10%80.
MRI data acquisition. We used a 3D pseudo-continuous Arterial Spin Labelling
(3D-pCASL) sequence to measure changes in regional Cerebral Blood Flow (rCBF)
over 15–120 min post-dosing. Labelling of arterial blood was achieved with a 1525
ms train of Hanning shaped RF pulses in the presence of a net magnetic field
gradient along the flow direction (the z-axis of the magnet). After a post-labelling
delay of 2025 ms, a whole-brain volume was read using a 3D interleaved “stack-of-
spirals” Fast Spin Echo readout81, consisting of eight interleaved spiral arms in the
in-plane direction, with 512 points per spiral interleave. TE was 11.088 ms and TR
was 5135 ms. 56 slice-partitions of 3 mm thickness were defined in the 3D readout.
The in-plane FOV was 240 × 240mm. The spiral sampling of k-space was re-
gridded to a rectangular matrix with an approximate in-plane resolution of
3.6 mm. The sequence acquired 5 control–label pairs. Individual CBF maps were
computed for each of the perfusion weighted difference images derived from every
control–label (C–L) pair, by scaling the difference images against a proton density
image acquired at the end of the sequence, using identical readout parameters. This
computation was done according to the formula suggested in the recent ASL
consensus article82. The sequence uses four background suppression pulses to
minimise static tissue signal at the time of image acquisition. We performed eight
of these 3D-pCASL sequence acquisitions, the acquisition time of each sequence
was 8:20 min. A 3D high-spatial-resolution, Magnetisation Prepared Rapid
Acquisition (3D MPRAGE) T1-weighted scan was acquired. Field of view was
270 mm, TR/TE/TI= 7.328/3.024/400 ms. The final resolution of the T1-weighted
image was 1.1 × 1.1 × 1.2 mm.
MRI data preprocessing. A multi-step approach was performed for the spatial
normalization of the CBF maps computed for each C–L pair to the space of the
Montreal Neurological Institute (MNI): (1) co-registration of the proton density
image from each sequence to the participant’s T1-image after resetting the origin of
both images to the anterior commissure. The transformation matrix of this co-
registration step was then applied to the CBF map from each C–L pair, to trans-
form the CBF map to the space of the T1-image; (2) unified segmentation of the T1
image; (3) elimination of extra-cerebral signal from the CBF map, by multiplication
of the “brain only” binary mask obtained in step [2], with each co-registered CBF
map; (4) normalization of the subject’s T1 image and the skull-stripped CBF maps
to the MNI152 space using the normalisation parameters obtained in step [2].
Finally, we spatially smoothed each normalized CBF map using an 8-mm Gaussian
smoothing kernel. All of these steps were implemented using the ASAP (Automatic
Software for ASL processing) toolbox (version 2.0)83. The resulting smoothed CBF
maps from each C-L pair were then averaged, using the fslmaths command
implemented in the FMRIB Software Library (FSL) software applications (https://
fsl.fmrib.ox.ac.uk/fsl/fslwiki/), to obtain a single averaged CBF map for each of the
time-intervals depicted in Fig. 1.
Physiological data acquisition and processing. Heart rate was continuously
monitored during the scanning period using MRI-compatible finger pulse oximetry
while the participant rested in supine position, breathing spontaneously in the
scanner. The data were recorded digitally as physiologic waveforms at a sampling
rate of 50 Hz. Heart beats were firstly automatically detected using an in-house
script and then visually inspected and manually cleaned for misidentified beats.
Inter-beat interval values were then calculated. The resulting cleaned data were
then transferred to Kubios HRV analysis software (MATLAB, version 2 beta,
Kuopio, Finland) and a set of time domain (heart-rate (HR) and the root mean
square of the successive differences (RMSSD), frequency domain (low (LF) and
high (HF) frequencies spectral powers and high/low frequency spectral power ratio
(HF/LF)) and nonlinear (Approximate entropy (ApEn), the SD1 and SD2 lines
from the Poincare Plot and the detrended fluctuation scaling exponents DFAα1
and DFAα2) analysis measures were calculated using the default Kubios
pipeline84,85. We decided to examinate a wide-range of different heart variability
measures because previous studies have diverged in the metrics where they found
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effects of OT on heart-rate variability84. For instance, there is currently debate
whether time and frequency analysis measures can be sufficiently sensitive to
capture important (nonlinear) changes in heart-rate time series, including those
changes associated with OT administration85–87. In addition to the manual
cleaning of the data, we also employed a threshold-based method of artefact cor-
rection, as provided by Kubios, where artefacts and ectopic beats were simply
corrected by comparing every RR interval value against a local average interval. The
threshold value used was 0.35 sec. Following current recommendations for heart-
rate data processing and analysis, if more than 5% of the beats required correction,
then we decided to exclude these periods of observation88. All of these metrics were
calculated based on the data recorded for the whole duration of each scan (8 min).
In some rare cases where artefacts could not be corrected, we only included the
data if at least 5 min of acquisition free of artefacts could be analysed. We based our
decision on the fact that at least 5 min of observation are required for pulse ple-
thysmography to reflect heart-rate variability as assessed by electrocardiography89.
The percentages of the total amount of available data used for this analysis after
data quality control can be found in Supplementary Table 4.
Statistical analyses. Global CBF Measures: We extracted mean global CBF values
within an explicit binary mask for grey-matter (derived from a standard T1-based
probabilistic map of grey-matter distribution by thresholding all voxels with a
probability >0.20) using the fslmeants command implemented in the FSL software
suite. We tested for the main effects of treatment and time-interval and for the
interaction between both factors on global CBF signal in a repeated measures
analysis of variance Treatment and Time as factors, implemented in SPSS 24
(http://www-01.ibm.com/software/uk/analytics/spss/), using the Greenhouse-
Geisser correction against violations of sphericity.
Subjective ratings: For the two subjective ratings of alertness and excitement
collected at the three timepoints post-dosing, we initially tested for the main effects of
treatment and time interval and for the interaction between both factors, as previously
described for global CBF. Second, we investigated the association between changes in
global CBF signal and self-ratings of alertness and excitement over time, using within-
group pooled correlation coefficients. For equal variances of the correlated variables in
the four subgroups, pooled within-group correlation coefficients represent a weighted
mean of the within-group correlation coefficients, weighted by the number of
observations in each subgroup90. They correspond to the result of statistically
eliminating subgroup differences from the total group correlation coefficient. Since we
only collected ratings at three timepoints, for this analysis we selected the global values
of the scans that were closer in time to the moment of the ratings acquisition. We
firstly inspected the equality of the covariance matrixes for each rating scale across the
four treatment groups to decide whether to pool the four groups or not, using the
mconvert command at SPSS. We then calculated the association between each rating
scale and global CBF for each participant and averaged the covariance matrices to
estimate the pooled within-group Pearson correlation coefficients. Results are
reported at a level of significance α= 0.05.
Whole-Brain univariate analyses: We firstly implemented an analysis of
covariance design, controlling for global effects on CBF, using a flexible factorial
model in SPM12 software (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/)
where we specified the factors Subjects, Treatment, and Time interval. We used
an F test to investigate the main effect of treatment, i.e. identify brain regions
where any treatment induced persistent changes in rCBF (regardless of
direction) across time and the main effect of time interval, i.e. identify brain
regions where any time-interval induced changes in rCBF (regardless of
direction), despite treatment. We also used an F test to investigate the
interaction of Treatment × Time-interval i.e. identify for brain regions showing
specific treatment-induced changes in rCBF as a function of time interval,
regardless of direction. Our study is novel in multiple ways: it is the first study to
investigate the pharmacodynamics effects of synthetic oxytocin on resting brain
physiology over an extended period of time when administered with any of the
three methods of administration we used in a double-blind placebo-controlled
crossover design. It is also the first in man study regarding the effects of OT
administered intravenously or with a nebulizer on rCBF. Since our study maps
uncharted territory, we followed up the flexible factorial model with an
exhaustive series of paired t-tests at each time interval to investigate the
direction of potential OT-induced changes in rCBF specifically for each
treatment route (compared to placebo). We conducted whole-brain cluster-level
inference for all analyses, reporting clusters significant at α= 0.05 using
familywise error (FWE) correction and a cluster-forming threshold of P= 0.005
(uncorrected). Our statistical thresholds were determined a priori based on our
own previous work investigating the effects of intranasal spray OT on rCBF in
humans16 and are standardly applied in pharmacological ASL studies measuring
rCBF91–96. For the paired t-tests, in recognition of the increased risk of false
positives given the large number of paired t-tests (3 × 8= 24), we mark clusters
that do not survive correction for multiple testing following adjustment of the P-
value using conservative Bonferroni correction for the 24 paired-t-tests
performed with an asterisk (*) (Padjusted= 0.05/24= 0.002) (see Tables 2–4).
Given the well-known decrease in global CBF across time (and in the absence of
a treatment × time interval interaction on global CBF values—see Results)16, we
included global CBF values as a nuisance covariate in our general linear model to
enhance sensitivity to detect OT-induced changes in regional CBF/neuronal
activation.
Regional temporal dynamics of pharmacological effects: We explored the time-
course of rCBF changes by estimating the mean rCBF values using the fslmeants
command in anatomical regions of interest (ROIs) corresponding to clusters
showing significant OT-induced rCBF changes (compared to placebo) for each
method of administration in the whole-brain univariate analyses. Specifically, we
defined anatomical ROIs for the left amygdala, anterior cingulate gyrus, left
caudate, left putamen, left globus pallidum, right visual cortex, left posterior insula
and left superior frontal gyrus using the Harvard-Oxford cortical and subcortical
atlases distributed with FSL. To maximize the amount of data points used to fit the
time-course functions (from 8 to 40 timepoints), at a cost of including noisier
estimates, we estimated mean ROI rCBF values of each of the 5 rCBF maps
corresponding to the 5 C-L pairs that were averaged to obtain the rCBF map for
each of the 8 time-intervals. We estimated the rCBF time-course for each ROI
implementing a non-parametric regression method that fits multiple regressions in
local neighbourhood (Locally estimated scatterplot smoothing - LOESS) using the
ggplot2 package from R97. This approach allows us to capture possible nonlinear
relationships between rCBF and time, while reducing the noise and without making
any assumptions about the relationship between these two variables. To control for
the potential confounding effects of the small changes in global CBF across time or
between methods of administration, we used demeaned rCBF estimates, which
correspond to estimating raw ROI mean rCBF minus global CBF values. Since we
performed these informative analyses a posteriori following the advice of one of our
reviewers, we did not run any statistical analysis on these extracted data, to avoid
double dipping. Instead, we provide these time-courses to illustrate the temporal
dynamics of OT-induced rCBF changes, by method of administration, for each key
brain region showing significant OT-induced changes in rCBF in the univariate
whole-brain analyses.
Pharmacokinetic analysis: From the plasmatic concentrations of OT at several
timepoints after dosing we calculated the area under the curve (AUC) using the
trapezoidal rule for each subject and session. AUC provides a single metric that
reflects variations in plasma levels of OT concentration following OT/placebo
administration for each session and each participant. We also determined the
absolute bioavailability of OT in systemic circulation for each of the intranasal
methods of administration, calculated as the dose-corrected AUC of each
intranasal administration divided by the dose-corrected AUC of the intravenous
administration. Mean AUCs were compared between the three methods of
administration with a repeated measures one-way analysis of variance, using the
Greenhouse-Geisser correction against violations of sphericity. Post-hoc
comparisons between methods were implemented using Tukey’s correction for
multiple comparisons. Mean absolute bioavailabilities were compared between the
standard nasal spray and the PARI SINUS nebulizer using a two-tailed paired t-test.
Association between OT-induced changes in rCBF and plasma OT: To
investigate if concomitant increases in peripheral OT were related to treatment-
induced changes in rCBF, we extracted data from each significant rCBF cluster
(adjusting for each treatment comparison contrast) in the paired sample t-tests
and calculated Spearman correlation coefficients between these contrasts
estimates and the AUCs reflecting individual differences in treatment-induced
OT plasma concentrations for the corresponding method of administration.
In this specific case, we employed the Spearman correlation coefficient because
the number of observations used to estimate the correlation is small, which does
not allow for an accurate verification of all implicit parametric analysis
assumptions.
OT effects on cardiac physiology: Previous human studies have shown the ability
of OT to affect cardiac physiology. Specifically, these studies have suggested that
intranasal OT increases HRV at rest85. HRV is an important index for the heart-
brain interaction98. Changes in HRV are accompanied by changes in the activity of
several areas of the brain, including the amygdala (one of the areas of the brain
most commonly implicated in OT effects on brain function and behaviour)99,100.
Thus, OT-induced changes in HRV, if existent, could account for, at least, some of
the OT-induced changes in rCBF we identify herein. We compared mean HR,
RMSSD, HF, LF, HF/LF ratio, ApEN, SD1, SD2, DFAα1 and DFAα2 between
methods of administration to examine the extent to which OT administration
induced changes in HR or heart-rate variability, by using a repeated measures two-
way analysis of variance. We used treatment and time interval as factors. We
determined main effects of time interval and treatment, as well as their interaction,
and used the Greenhouse-Geisser correction against violations of sphericity. We
contained the false-discovery rate (FDR) at α= 0.05 using the Benjamini-Hochberg
procedure, which is a more powerful version of the Bonferroni adjustment that
allows non-independence between statistical tests101. Original p-values (two-tailed)
are reported alongside with values obtained after accounting for FDR.
All the analyses were conducted with the researcher unblinded regarding
treatment condition102. Since we used a priori and commonly accepted statistical
thresholds and report all observed results at these thresholds—the risk of bias in
our analyses is therefore minimal, if not null.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
Data can be accessed from the corresponding author upon reasonable request. A
reporting summary for this Article is available as a Supplementary Information file. The
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Table 5 are provided as a Source data file.
Received: 25 February 2019; Accepted: 4 February 2020;
References
1. Miller, T. V. & Caldwell, H. K. Oxytocin during development: possible
organizational effects on behavior. Front. Endocrinol. (Lausanne) 6, 76 (2015).
2. Churchland, P. S. & Winkielman, P. Modulating social behavior with
oxytocin: how does it work? What does it mean? Horm. Behav. 61, 392–399
(2012).
3. Johnson, Z. V. & Young, L. J. Oxytocin and vasopressin neural networks:
implications for social behavioral diversity and translational neuroscience.
Neurosci. Biobehav Rev. 76, 87–98 (2017).
4. Tracy, L. M., Georgiou-Karistianis, N., Gibson, S. J. & Giummarra, M. J.
Oxytocin and the modulation of pain experience: Implications for chronic
pain management. Neurosci. Biobehav Rev. 55, 53–67 (2015).
5. Leslie, M., Silva, P., Paloyelis, Y., Blevins, J. & Treasure, J. A systematic review
and quantitative meta-analysis of oxytocin’s effects on feeding. J.
Neuroendocrinol. https://doi.org/10.1111/jne.12584 (2018).
6. Karelina, K. et al. Oxytocin mediates social neuroprotection after cerebral
ischemia. Stroke 42, 3606–3611 (2011).
7. Anagnostou, E. et al. Intranasal oxytocin in the treatment of autism spectrum
disorders: a review of literature and early safety and efficacy data in youth.
Brain Res. 1580, 188–198 (2014).
8. Shilling, P. D. & Feifel, D. Potential of oxytocin in the treatment of
schizophrenia. CNS Drugs 30, 193–208 (2016).
9. Tzabazis, A. et al. Oxytocin and migraine headache. Headache 57(Suppl 2),
64–75 (2017).
10. Olszewski, P. K., Klockars, A. & Levine, A. S. Oxytocin and potential benefits
for obesity treatment. Curr. Opin. Endocrinol. Diabetes Obes. 24, 320–325
(2017).
11. Rice, L. J., Einfeld, S. L., Hu, N. & Carter, C. S. A review of clinical trials of
oxytocin in Prader-Willi syndrome. Curr. Opin. Psychiatry 31, 123–127
(2018).
12. Ermisch, A. et al. On the blood-brain barrier to peptides: accumulation of
labelled vasopressin, DesGlyNH2-vasopressin and oxytocin by brain regions.
Endocrinol. Exp. 19, 29–37 (1985).
13. Born, J. et al. Sniffing neuropeptides: a transnasal approach to the human
brain. Nat. Neurosci. 5, 514–516 (2002).
14. Quintana, D. S., Smerud, K. T., Andreassen, O. A. & Djupesland, P. G.
Evidence for intranasal oxytocin delivery to the brain: recent advances and
future perspectives. Ther. Deliv. 9, 515–525 (2018).
15. Leng, G. & Ludwig, M. Intranasal oxytocin: myths and delusions. Biol.
Psychiatry 79, 243–250 (2016).
16. Paloyelis, Y. et al. A spatiotemporal profile of in vivo cerebral blood flow changes
following intranasal oxytocin in humans. Biol. Psychiatry 79, 693–705 (2016).
17. Vyas, T. K., Shahiwala, A., Marathe, S. & Misra, A. Intranasal drug delivery for
brain targeting. Curr. Drug Deliv. 2, 165–175 (2005).
18. Beard, R., Singh, N., Grundschober, C., Gee, A. D. & Tate, E. W. High-yielding
(18)F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-
brain oxytocin uptake in vivo. Chem. Commun. (Camb.) 54, 8120–8123
(2018).
19. Guastella, A. J. & MacLeod, C. A critical review of the influence of oxytocin
nasal spray on social cognition in humans: evidence and future directions.
Horm. Behav. 61, 410–418 (2012).
20. Evans, S. L., Dal Monte, O., Noble, P. & Averbeck, B. B. Intranasal oxytocin
effects on social cognition: a critique. Brain Res. 1580, 69–77 (2014).
21. Hollander, E. et al. Oxytocin infusion reduces repetitive behaviors in adults
with autistic and Asperger’s disorders. Neuropsychopharmacology 28, 193–198
(2003).
22. Hollander, E. et al. Oxytocin increases retention of social cognition in autism.
Biol. Psychiatry 61, 498–503 (2007).
23. Robinson, K. J., Twiss, S. D., Hazon, N., Moss, S. & Pomeroy, P. P. Positive
social behaviours are induced and retained after oxytocin manipulations
mimicking endogenous concentrations in a wild mammal. Proc. Biol. Sci.
https://doi.org/10.1098/rspb.2017.0554 (2017).
24. Drago, F., Pedersen, C. A., Caldwell, J. D. & Prange, A. J. Jr. Oxytocin potently
enhances novelty-induced grooming behavior in the rat. Brain Res. 368,
287–295 (1986).
25. Bitter, C., Suter-Zimmermann, K. & Surber, C. Nasal drug delivery in humans.
Curr. Probl. Dermatol 40, 20–35 (2011).
26. Illum, L. Nasal drug delivery—recent developments and future prospects. J.
Control Release 161, 254–263 (2012).
27. Handley, R. et al. Acute effects of single-dose aripiprazole and haloperidol on
resting cerebral blood flow (rCBF) in the human brain. Hum. Brain Mapp. 34,
272–282 (2013).
28. Doyle, O. M. et al. Quantifying the attenuation of the ketamine
pharmacological magnetic resonance imaging response in humans: a
validation using antipsychotic and glutamatergic agents. J. Pharm. Exp. Ther.
345, 151–160 (2013).
29. Hodkinson, D. J. et al. Quantifying the test-retest reliability of cerebral blood
flow measurements in a clinical model of on-going post-surgical pain: A study
using pseudo-continuous arterial spin labelling. Neuroimage Clin. 3, 301–310
(2013).
30. Drake, C. T. & Iadecola, C. The role of neuronal signaling in controlling
cerebral blood flow. Brain Lang. 102, 141–152 (2007).
31. Dukart, J. et al. Cerebral blood flow predicts differential neurotransmitter
activity. Sci. Rep. 8, 4074 (2018).
32. Xi, J. et al. Visualization and quantification of nasal and olfactory deposition
in a sectional adult nasal airway cast. Pharm. Res 33, 1527–1541 (2016).
33. Djupesland, P. G., Mahmoud, R. A. & Messina, J. C. Accessing the brain: the
nose may know the way. J. Cereb. Blood Flow. Metab. 33, 793–794 (2013).
34. Radke, S. et al. Oxytocin reduces amygdala responses during threat approach.
Psychoneuroendocrinology 79, 160–166 (2017).
35. Spengler, F. B. et al. Kinetics and dose dependency of intranasal oxytocin
effects on amygdala reactivity. Biol. Psychiatry 82, 885–894 (2017).
36. Geng, Y. et al. Oxytocin enhancement of emotional empathy: generalization
across cultures and effects on amygdala activity. Front. Neurosci. 12, 512 (2018).
37. Rosenfeld, A. J., Lieberman, J. A. & Jarskog, L. F. Oxytocin, dopamine, and the
amygdala: a neurofunctional model of social cognitive deficits in
schizophrenia. Schizophr. Bull. 37, 1077–1087 (2011).
38. Campbell-Smith, E. J., Holmes, N. M., Lingawi, N. W., Panayi, M. C. &
Westbrook, R. F. Oxytocin signaling in basolateral and central amygdala
nuclei differentially regulates the acquisition, expression, and extinction of
context-conditioned fear in rats. Learn. Mem. (Cold Spring Harb., N. Y.) 22,
247–257 (2015).
39. Kirsch, P. et al. Oxytocin modulates neural circuitry for social cognition and
fear in humans. J. Neurosci. 25, 11489–11493 (2005).
40. Apps, M. A., Rushworth, M. F. & Chang, S. W. The anterior cingulate gyrus
and social cognition: tracking the motivation of others. Neuron 90, 692–707
(2016).
41. Etkin, A., Egner, T. & Kalisch, R. Emotional processing in anterior cingulate
and medial prefrontal cortex. Trends Cogn. Sci. 15, 85–93 (2011).
42. Milad, M. R. et al. A role for the human dorsal anterior cingulate cortex in fear
expression. Biol. Psychiatry 62, 1191–1194 (2007).
43. Kleckner, I. R. et al. Evidence for a Large-Scale Brain System Supporting
Allostasis and Interoception in Humans. Nat. Hum. Behav. https://doi.org/
10.1038/s41562-017-0069 (2017).
44. Chini, B., Verhage, M. & Grinevich, V. The action radius of oxytocin release in
the mammalian CNS: from single vesicles to behavior. Trends Pharm. Sci. 38,
982–991 (2017).
45. Lee, M. R. et al. Oxytocin by intranasal and intravenous routes reaches the
cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin
assay. Mol. Psychiatry 23, 115–122 (2018).
46. Smith, A. S., Korgan, A. C. & Young, W. S. Oxytocin delivered nasally or
intraperitoneally reaches the brain and plasma of normal and oxytocin
knockout mice. Pharm. Res. 146, 104324 (2019).
47. Yamamoto, Y. et al. Vascular RAGE transports oxytocin into the brain to elicit
its maternal bonding behaviour in mice. Commun. Biol. 2, 76 (2019).
48. Russell, J. A., Leng, G. & Douglas, A. J. The magnocellular oxytocin system,
the fount of maternity: adaptations in pregnancy. Front. Neuroendocrinol. 24,
27–61 (2003).
49. Chini, B. & Manning, M. Agonist selectivity in the oxytocin/vasopressin receptor
family: new insights and challenges. Biochem. Soc. Trans. 35, 737–741 (2007).
50. Quintana, D. S. et al. Low dose intranasal oxytocin delivered with Breath
Powered device dampens amygdala response to emotional stimuli: A
peripheral effect-controlled within-subjects randomized dose-response fMRI
trial. Psychoneuroendocrinology 69, 180–188 (2016).
51. Busnelli, M. & Chini, B. Molecular basis of oxytocin receptor signalling in the
brain: what we know and what we need to know. Curr. Top. Behav. Neurosci.
35, 3–29 (2018).
52. Martin, B. et al. Class II G protein-coupled receptors and their ligands in
neuronal function and protection. Neuromol. Med. 7, 3–36 (2005).
53. Lochhead, J. J. & Thorne, R. G. Intranasal delivery of biologics to the central
nervous system. Adv. Drug Deliv. Rev. 64, 614–628 (2012).
54. Shipley, M. T. Transport of molecules from nose to brain: transneuronal
anterograde and retrograde labeling in the rat olfactory system by wheat germ
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14845-5
14 NATURE COMMUNICATIONS |         (2020) 11:1160 | https://doi.org/10.1038/s41467-020-14845-5 | www.nature.com/naturecommunications
agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res.
Bull. 15, 129–142 (1985).
55. Balin, B. J., Broadwell, R. D., Salcman, M. & Elkalliny, M. Avenues for entry of
peripherally administered protein to the central-nervous-system in mouse, rat,
and squirrel-monkey. J. Comp. Neurol. 251, 260–280 (1986).
56. Frey, W. H. et al. Delivery of I-125-NGF to the brain via the olfactory route.
Drug Deliv. 4, 87–92 (1997).
57. Kumar, N. N. et al. Delivery of immunoglobulin G antibodies to the rat
nervous system following intranasal administration: Distribution, dose-
response, and mechanisms of delivery. J. Control Release 286, 467–484
(2018).
58. Thorne, R. G., Hanson, L. R., Ross, T. M., Tung, D. & Frey, W. H. 2nd
Delivery of interferon-beta to the monkey nervous system following intranasal
administration. Neuroscience 152, 785–797 (2008).
59. Beard, R., Singh, N., Grundschober, C., Gee, A. D. & Tate, E. W. High-yielding
F-18 radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-
brain oxytocin uptake in vivo. Chem. Commun. 54, 8120–8123 (2018).
60. Hochheimer, A. et al. Endogenous gustatory responses and gene expression
profile of stably proliferating human taste cells isolated from fungiform
papillae. Chem. Senses 39, 359–377 (2014).
61. Levasseur, G. et al. Anatomical and functional evidence for a role of arginine-
vasopressin (AVP) in rat olfactory epithelium cells. Eur. J. Neurosci. 20,
658–670 (2004).
62. Baribeau, D. A. & Anagnostou, E. Oxytocin and vasopressin: linking pituitary
neuropeptides and their receptors to social neurocircuits. Front Neurosci. 9,
335 (2015).
63. Quintana, D. S. et al. Oxytocin pathway gene networks in the human brain.
Nat. Commun. 10, 668 (2019).
64. Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26,
1261–1268 (2008).
65. Declerck, C. H., Lambert, B. & Boone, C. Sexual dimorphism in oxytocin
responses to health perception and disgust, with implications for theories on
pathogen detection. Horm. Behav. 65, 521–526 (2014).
66. Luo, L. et al. Sex-dependent neural effect of oxytocin during subliminal
processing of negative emotion faces. Neuroimage 162, 127–137 (2017).
67. Gao, S. et al. Oxytocin, the peptide that bonds the sexes also divides them.
Proc. Natl Acad. Sci. USA 113, 7650–7654 (2016).
68. Hirano, Y., Stefanovic, B. & Silva, A. C. Spatiotemporal evolution of the
functional magnetic resonance imaging response to ultrashort stimuli. J.
Neurosci. Off. J. Soc. Neurosci. 31, 1440–1447 (2011).
69. Ma, Y. et al. Resting-state hemodynamics are spatiotemporally coupled to
synchronized and symmetric neural activity in excitatory neurons. Proc. Natl
Acad. Sci. USA 113, E8463–E8471 (2016).
70. Wang, D. J., Chen, Y., Fernandez-Seara, M. A. & Detre, J. A. Potentials and
challenges for arterial spin labeling in pharmacological magnetic resonance
imaging. J. Pharmacol. Exp. Ther. 337, 359–366 (2011).
71. Galbusera, A. et al. Intranasal oxytocin and vasopressin modulate divergent
brainwide functional substrates. Neuropsychopharmacology 42, 1420–1434
(2017).
72. Ruis, C. et al. Symptom Checklist 90-Revised in neurological outpatients. J.
Clin. Exp. Neuropsychol. 36, 170–177 (2014).
73. Sacco, R. et al. Psychometric properties and validity of Beck Depression
Inventory II in multiple sclerosis. Eur. J. Neurol. 23, 744–750
(2016).
74. Murphy, K. et al. Pulsed arterial spin labeling perfusion imaging at 3 T:
estimating the number of subjects required in common designs of clinical
trials. Magn. Reson. Imaging 29, 1382–1389 (2011).
75. MacDonald, E. et al. A review of safety, side-effects and subjective reactions to
intranasal oxytocin in human research. Psychoneuroendocrinology 36,
1114–1126 (2011).
76. Moeller, W. et al. Ventilation and aerosolized drug delivery to the paranasal
sinuses using pulsating airflow - a preliminary study. Rhinology 47, 405–412
(2009).
77. Sarna, M. C., Soni, A. K., Gomez, M. & Oriol, N. E. Intravenous oxytocin in
patients undergoing elective cesarean section. Anesth. Analg. 84, 753–756
(1997).
78. Thomas, J. S., Koh, S. H. & Cooper, G. M. Haemodynamic effects of oxytocin
given as i.v. bolus or infusion on women undergoing Caesarean section. Br. J.
Anaesth. 98, 116–119 (2007).
79. Szeto, A. et al. Evaluation of enzyme immunoassay and radioimmunoassay
methods for the measurement of plasma oxytocin. Psychosom. Med. 73,
393–400 (2011).
80. Kagerbauer, S. M. et al. Plasma oxytocin and vasopressin do not predict
neuropeptide concentrations in human cerebrospinal fluid. J.
Neuroendocrinol. 25, 668–673 (2013).
81. Thedens, D. R., Irarrazaval, P., Sachs, T. S., Meyer, C. H. & Nishimura, D. G.
Fast magnetic resonance coronary angiography with a three-dimensional stack
of spirals trajectory. Magn. Reson Med. 41, 1170–1179 (1999).
82. Alsop, D. C. et al. Recommended implementation of arterial spin-labeled
perfusion MRI for clinical applications: A consensus of the ISMRM perfusion
study group and the European consortium for ASL in dementia. Magn. Reson
Med. 73, 102–116 (2015).
83. Mato Abad, V., Garcia-Polo, P., O’Daly, O., Hernandez-Tamames, J. A. &
Zelaya, F. ASAP (Automatic Software for ASL Processing): A toolbox for
processing Arterial Spin Labeling images. Magn. Reson Imaging 34, 334–344
(2016).
84. Weissman, A., Tobia, R. S., Burke, Y. Z., Maxymovski, O. & Drugan, A. The
effects of oxytocin and atosiban on the modulation of heart rate in pregnant
women. J. Matern.-fetal neonatal Med.: Off. J. Eur. Assoc. Perinat. Med.,
Federation Asia Ocean. Perinat. Societies, Int. Soc. Perinat. Obstet. 30, 329–333
(2017).
85. Kemp, A. H. et al. Oxytocin increases heart rate variability in humans at rest:
implications for social approach-related motivation and capacity for social
engagement. PLOS ONE, https://doi.org/10.1371/journal.pone.0044014 (2012).
86. Huikuri, H. V., Perkiomaki, J. S., Maestri, R. & Pinna, G. D. Clinical impact of
evaluation of cardiovascular control by novel methods of heart rate dynamics.
Philos. Trans. A Math. Phys. Eng. Sci. 367, 1223–1238 (2009).
87. Tracy, L. M., Gibson, S. J., Labuschagne, I., Georgiou-Karistianis, N. &
Giummarra, M. J. Intranasal oxytocin reduces heart rate variability during a
mental arithmetic task: A randomised, double-blind, placebo-controlled cross-
over study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 81, 408–415 (2018).
88. Billman, G. E., Huikuri, H. V., Sacha, J. & Trimmel, K. An introduction to
heart rate variability: methodological considerations and clinical applications.
Front. Physiol. 6, 55 (2015).
89. Selvaraj, N., Jaryal, A., Santhosh, J., Deepak, K. K. & Anand, S. Assessment
of heart rate variability derived from finger-tip photoplethysmography as
compared to electrocardiography. J. Med. Eng. Technol. 32, 479–484 (2008).
90. Sockloff, A. L. Behavior of product-moment correlation coefficient when 2
heterogeneous subgroups are pooled. Educ. Psychol. Meas. 35, 267–276 (1975).
91. Mutsaerts, H. et al. Cerebral perfusion changes in presymptomatic genetic
frontotemporal dementia: a GENFI study. Brain: a J. Neurol. 142, 1108–1120
(2019).
92. Takeuchi, H. et al. Cerebral blood flow during rest associates with general
intelligence and creativity. PLoS ONE 6, e25532 (2011).
93. Joe, A. Y. et al. Response-dependent differences in regional cerebral blood flow
changes with citalopram in treatment of major depression. J. Nucl. Med. 47,
1319–1325 (2006).
94. Thomas, B. P. et al. Life-long aerobic exercise preserved baseline cerebral
blood flow but reduced vascular reactivity to CO2. J. Magn. Reson Imaging 38,
1177–1183 (2013).
95. Loggia, M. L. et al. Default mode network connectivity encodes clinical pain:
an arterial spin labeling study. Pain 154, 24–33 (2013).
96. Nwokolo, M. et al. Hypoglycemic thalamic activation in type 1 diabetes is
associated with preserved symptoms despite reduced epinephrine. J. Cereb.
Blood. Flow Metab., 271678X19842680, https://doi.org/10.1177/
0271678X19842680 (2019).
97. Villanueva, R. A. M. & Chen, Z. J. ggplot2: elegant graphics for data analysis,
2nd edition. Meas.-Interdiscip. Res. 17, 160–167 (2019).
98. Kurisu, S. & Kihara, Y. Interaction between brain and heart. Circ. J. 80,
1905–1906 (2016).
99. Wallentin, M. et al. Amygdala and heart rate variability responses from listening
to emotionally intense parts of a story. Neuroimage 58, 963–973 (2011).
100. Sakaki, M. et al. Heart rate variability is associated with amygdala functional
connectivity with MPFC across younger and older adults. Neuroimage 139,
44–52 (2016).
101. Feser, W. J., Fingerlin, T. E., Strand, M. J. & Glueck, D. H. Calculating average
power for the benjamini-hochberg procedure. J. Stat. Theory Appl. 8, 325–352
(2009).
102. Gryglewski, G. et al. Spatial analysis and high resolution mapping of the
human whole-brain transcriptome for integrative analysis in neuroimaging.
Neuroimage 176, 259–267 (2018).
Acknowledgements
We would like to thank Mr. Robert Taylor for his help in organizing the pulse ple-
tismography data and Dr. Elena Makovac for her help with heart-rate variability data
analysis. This study was part-funded by: an Economic and Social Research Council Grant
(ES/K009400/1) to Y.P.; scanning time support by the National Institute for Health
Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS
Foundation Trust and King’s College London to Y.P.; an unrestricted research grant by
PARI GmbH to Y.P.
Author contributions
Y.P. designed the study; Y.P., S.V., J.L. collected the data; N.M., A.O. and S.M. provided
medical supervision and carried out medical procedures; D.A.M. analyzed the data; U.S.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14845-5 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1160 | https://doi.org/10.1038/s41467-020-14845-5 | www.nature.com/naturecommunications 15
and S.W. provided new analytical tools; D.A.M. and Y.P. interpreted the results and
wrote the first draft of the paper; M.M., M.H., F.Z., S.C.R.W., D.M., G.M. and A.F.
revised the manuscript for intellectual content.
Competing interests
The authors declare no competing interests. This manuscript represents independent
research. The views expressed are those of the authors and not necessarily those of the
NHS, the NIHR, the Department of Health and Social Care, or PARI GmbH.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-14845-5.
Correspondence and requests for materials should be addressed to Y.P.
Peer review information Nature Communications thanks Gareth Leng and the other,
anonymous, reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in
a credit line to the material. If material is not included in the article’s Creative Commons
license and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14845-5
16 NATURE COMMUNICATIONS |         (2020) 11:1160 | https://doi.org/10.1038/s41467-020-14845-5 | www.nature.com/naturecommunications
